v3.26.1
Financial Royalty Assets, net (Tables)
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Financial Royalty Assets
Financial royalty assets consist of the following (in thousands):
June 30, 2026December 31, 2025
Gross carrying value(1)
Allowance
Net carrying value (1)
Gross carrying value(1)
Allowance
Net carrying value(1)
Qarziba$101,303 $(468)$100,835 $118,593 $(498)$118,095 
Agenus Bot/Bal40,815 (408)40,407 40,815 (408)40,407 
Tolerance Therapeutics (Tzield®)
25,470 (99)25,371 25,257 (98)25,159 
Ohtuvayre inventors19,957 (179)19,778 16,921 (151)16,770 
Elutia (CorMatrix)6,062 (837)5,225 6,607 (1,107)5,500 
AT2204,442 (109)4,333 5,132 (132)5,000 
Primrose mRNA3,281 (98)3,183 3,281 (98)3,183 
Zerion2,640 (79)2,561 — — — 
Others5,729 (212)5,517 5,769 (214)5,555 
Total financial royalty assets, net$209,699 $(2,489)$207,210 $222,375 $(2,706)$219,669 
(1) The amounts include the short-term portion of financial royalty assets, which represents our estimate of current-quarter royalty receipts expected to be collected in the subsequent quarter. The short-term portion of financial royalty assets totaled $13.0 million and $22.8 million and was presented as a separate line item in our condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively.